Effects of selective cyclooxygenase-2 and nonselective cyclooxygenase inhibition on ischemic myocardium.
OBJECTIVE
We explored effects of nonselective cyclooxygenase and selective cyclooxygenase 2 inhibition on collateral development in a model of chronic myocardial ischemia. We hypothesized that cyclooxygenase 2 inhibitors would negatively effect angiogenic and inflammatory pathways.


METHODS
Yorkshire swine were made chronically ischemic by placing an ameroid constrictor on the left circumflex coronary artery. Swine were divided into 3 groups and given no drug (control, n = 7), a nonselective cyclooxygenase inhibitor (naproxen 400 mg daily, n = 7), or a selective cyclooxygenase 2 inhibitor (celecoxib 200 mg daily, n = 7). After 7 weeks, coronary angiography was performed. Myocardial function and microvascular reactivity were assessed. Serum and myocardial tissue were analyzed for prostaglandin levels and markers of inflammation and angiogenesis.


RESULTS
The celecoxib group demonstrated significantly increased mean arterial pressure and decreased left ventricular function. Myocardial perfusion in the celecoxib group was similar to control value but less than in the naproxen group. Coronary microvascular contraction in the collateral-dependent territory was increased in the naproxen group but minimally affected in the celecoxib group. Oxidative stress and apoptosis were increased in the celecoxib group. Expression of angiogenic markers vascular endothelial growth factor and phospho-endothelial nitric oxide synthase (ser1177) and tissue levels of prostacyclin were decreased in both celecoxib and naproxen groups. The naproxen group had diminished endostatin expression.


CONCLUSIONS
Selective and nonselective cyclooxygenase inhibition are more complex in effect than previously published, but they did not decrease collateral-dependent blood flow to the myocardium in our model of chronic myocardial ischemia.
Robich
Michael P
MP
Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert School of Medicine, Brown University, Providence, RI 02903, USA.
Chu
Louis M
LM
Feng
Jun
J
Burgess
Thomas A
TA
Laham
Roger J
RJ
Bianchi
Cesario
C
Sellke
Frank W
FW
D042501:Angiogenic Proteins / Q000378:metabolism; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D000068579:Celecoxib; D003097:Collateral Circulation / Q000187:drug effects; D017023:Coronary Angiography; D003326:Coronary Circulation / Q000187:drug effects*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000633:toxicity*; D016861:Cyclooxygenase Inhibitors / Q000633:toxicity*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006339:Heart Rate / Q000187:drug effects; D018836:Inflammation Mediators / Q000378:metabolism; D008833:Microcirculation / Q000187:drug effects; D017202:Myocardial Ischemia / Q000175:diagnosis / Q000201:enzymology* / Q000503:physiopathology; D055414:Myocardial Perfusion Imaging; D009206:Myocardium / Q000201:enzymology* / Q000473:pathology; D009288:Naproxen / Q000633:toxicity*; D018919:Neovascularization, Physiologic / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D011453:Prostaglandins / Q000378:metabolism; D011720:Pyrazoles / Q000633:toxicity*; D013449:Sulfonamides / Q000633:toxicity*; D013552:Swine; D013556:Swine, Miniature; D013997:Time Factors; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology; D016277:Ventricular Function, Left / Q000187:drug effects
D042501:Angiogenic Proteins; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D018836:Inflammation Mediators; D011453:Prostaglandins; D011720:Pyrazoles; D013449:Sulfonamides; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; D009288:Naproxen; D051546:Cyclooxygenase 2; D000068579:Celecoxib
JAMA. 2006 Oct 4;296(13):1619-32
16968832
J Hum Hypertens. 1996 Apr;10(4):257-61
8736458
J Clin Invest. 2006 May;116(5):1391-9
16614756
Cardiovasc Res. 2006 Feb 1;69(2):512-9
16336951
J Cardiovasc Pharmacol. 2007 Nov;50(5):470-9
18030055
Am J Cardiol. 2009 May 1;103(9):1227-37
19406264
Cell Death Differ. 2006 Jul;13(7):1110-22
16273080
Neuro Oncol. 2002 Jan;4(1):1-8
11772427
Circulation. 2003 Mar 18;107(10):1418-23
12642364
Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2420-9
12881220
Circulation. 2007 Aug 28;116(9):975-83
17679611
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272-7
9874808
J Thorac Cardiovasc Surg. 2003 Jun;125(6):1481-92
12830070
Circulation. 1998 Nov 10;98(19 Suppl):II242-6; discussion II247-8
9852909
Cardiovasc Res. 1995 Nov;30(5):697-704
8595615
Am J Physiol. 1984 Sep;247(3 Pt 2):H452-8
6433725
J Thorac Cardiovasc Surg. 2008 Jan;135(1):117-22
18179927
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):12908-13
8917518
Br J Pharmacol. 2002 Mar;135(6):1540-6
11906968
J Thorac Cardiovasc Surg. 2010 May;139(5):1253-60, 1260.e1-2
20412960
N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528
11087881
Ann Intern Med. 1994 Aug 15;121(4):289-300
8037411
N Engl J Med. 2005 Mar 17;352(11):1071-80
15713944
Cancer Immunol Immunother. 2008 Mar;57(3):347-58
17668203
Circulation. 2008 Apr 22;117(16):2104-13
18378608